Investor Presentaiton
HANBEITAI (Bevacizumab): Commercialization Acceleration in 2023
14
贝伐珠单抗注射液
100 mg(4 m/
Acceleration on market access
and penetration
119M RMB
•
Covered by NRDL in 31 provinces, and
Revenue in 2023
Henlius
贝伐珠单抗注射液
汉贝泰 Ⓡ
100 mg(4 ml)/
•
•
Exploration for new medication
methods
completed tendering and procurement platform
listing in 28 provinces
Focus on the dual-channel markets, and
enhance market recognition to drive sales
growth
Proactively seek for hospitals access in non
dual-channel markets
Proactively participate in provincial VBP
programs
•
The only bevacizumab biosimilars with phase III
clinical data on metastatic colorectal cancer in
China
Potentially can combine with HANSIZHUANG
(anti-PD-1 mAb) to treating multiple tumor types
in a combo therapy
Ⓒ Target: VEGF Indications:
2024 Henlius.
•
Metastatic colorectal cancer
Advanced, metastatic or recurrent NSCLC
•
Recurrent glioblastoma
•
Cervical cancer
•
Drug Specifications:
100mg/4ml/bottle
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
2 HenliusView entire presentation